Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).
Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing. This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.